Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-08-27
2010-02-16
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07662780
ABSTRACT:
The invention provides compositions and methods for treatment and prophylaxis of weight disorders. Such methods entail administering to an individual a therapeutically or prophylactically effective dosage regime of a hypocretin or an agonist thereof, and monitoring the condition of the individual responsive to the administering.
REFERENCES:
patent: 7112566 (2006-09-01), Siegel et al.
patent: 7335640 (2008-02-01), Siegel et al.
patent: 98/05352 (1998-02-01), None
Taheri et al., Clinical Science (2001) 101(2, Supplement 45):17p. and Table of Contents.
Alberts et al. 1994. Molecular Biology of the Cell pp. 129-130.
Stricker-Krongrad 2002 Regulatory Peptides 104:11-20.
Haynes, Andrea C., et al., “Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat,” Peptides 20 (1999) 1099-1105.
Preti, Antonio, “Orexins (hypocretins): Their role in appetite and arousal,” Current Opinion in Investigational Drugs 2002, 3(8), 1199-1206.
De Lecea L, Kilduff T, Peyron C, Gao XB, Foye PE, Danielson PE, Fukahara C, Battenberg Elf, Gautvik VT, Barlett FS, Frankel WN, Van Den Pol AN, Bloom F, Gautvik KM, Sutcliffe JG (1998) The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95:322-327.
Dube MG, Kalra SP, Kalra PS (1999) Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res 842:473-477.
Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, Bloom SR (1999) The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin. J. Endocrinol. 160:R7-12.
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345-354.
Ida T, Nakahara K, Katayama T, Murakami N, Nakazato M (1999) Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res 821:526-529.
John J, Wu MF, Siegel JM (2000) Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res. Online 3:23-28 http://www.sro.org/2000/John/23/.
Kiyashchenko Li, Mileykovskiy BY, Lai YY, Siegel JM (2001) Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J. Neurophysiol. 85:2008-2016.
Levitt DR, Teitelbaum P (1975) Somnolence, akinesia, and sensory activation of motivated behavior in the lateral hypothalamic syndrome. Proc. Natl. Acad. Sci. U.S.A. 72:2819-2823.
Lin L. Faraco J, Kadotani H, Rogers W, Lin X, Qui X, De Jong P, Nishino S, Mignot E (1999) The REM sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor gene. Cell 98:365-376.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, Mcnulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585.
Schuld A, Hebebrand J, Geller F, Pollmacher T (2000) Increased body-mass index in patients with narcolepsy. Lancet 355:1274-1275.
Siegel JM (1999) Narcolepsy: A key role for hypocretins (orexins). Cell 98:409-412.
Sweet DC, Levine AS, Billington CJ, Kotz CM (1999) Feeding response to central orexins. Brain Res 821:535-538.
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469-474.
Tritos NA, Mastaitis JW, Kokkotou E, Maratos-Flier E (2001) Characterization of melanin concentrating hormone and preproorexin expression in the murine hypothalamus. Brain Res 895:160-166.
Willie JT, Chemelli RM, Sinton CM, Yanagisawa M (2001) To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci. 24:429-458.
Yamamato Y, Ueta Y, Date Y, Nakazato M, Hara Y, Serino R, Nomura M, Shibuya I, Matsukura S, Yamashita H (1999) Down regulation of the prepro-orexin gene expression in genetically obese mice. Brain Res Mol Brain Res 65:14-22.
Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K (1999) Chronic intracerebroventricular administration of orexin-a to rats increases food intake in daytime, but has no effect on body weight. Brain Res 849:248-252.
Murillo Lisa Noelle Boehmer
Siegel Jerome
Kolker Daniel E.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
Administering hypocretin to obese individuals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administering hypocretin to obese individuals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administering hypocretin to obese individuals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4159940